虽然前哨淋巴结活检(SLNB)在早期乳腺癌治疗中的应用已写入治疗指南,但SLNB仍存在假阴性问题,SLNB的地位尚有待于大样本随机对照研究的随访结果。目前在临床应用中,可以通过控制SLNB的适应证、优化和标准化SLNB技术、以SLN导航的腋淋巴结群切除为代表的改良方法来降低SLNB的假阴性率。 Although the use of sentinel lymph node biopsy (SLNB) in the treatment of early breast cancer has been written into the treatment guidelines, there is still a problem of false negatives in SLNB. The status of SLNB remains to be seen in large randomized controlled trials. At present, in clinical application, the false negative rate of SLNB can be reduced by controlling the indications of SLNB, optimizing and standardizing SLNB technology, and improving the method represented by axillary lymph node dissection with SLN navigation.